Application of human amniotic epithelial cells in preparation of medicine for preventing or treating senile asthenia

A technology for senile debilitation and epithelial cells, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical raw materials derived from mammals, etc., to achieve the effect of simple separation methods, improved living conditions, and no ethical problems

Pending Publication Date: 2020-10-23
上海安库生医生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the isolation method of human amniotic epithelial cells is simple, has no ethical problems and no tumorigenicity, and has multi-directional differentiation and immune regulation capabilities, and can also be widely used in the fields of cell therapy and tissue regeneration. Application reports for preventing or treating frailty in the elderly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human amniotic epithelial cells in preparation of medicine for preventing or treating senile asthenia
  • Application of human amniotic epithelial cells in preparation of medicine for preventing or treating senile asthenia
  • Application of human amniotic epithelial cells in preparation of medicine for preventing or treating senile asthenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The human amniotic epithelial cells used in this example are the P3 generation cells isolated and cultured from human amniotic membrane. Select 20 (10 male and 10 male) healthy mice with similar body weight at the age of 8-10 and no clinical symptoms after observation. Two groups, the experimental group and the control group, with 10 mice in each group (5 female mice and 5 male mice), were weighed and recorded. The experimental group was given therapeutic agents (ingredients: containing 1×10 6 Human amniotic epithelial cells (0.5mL normal saline), the control group was given placebo (ingredient: 0.5mL normal saline), tail vein injection administration. After 2 months, observe the clinical symptoms (observation in separate cages, the observation contents include whether death, dying, activity status, appearance and coat, trauma, feces, etc.), and weigh them. Then the mice were dissected, and the main organs (heart, liver, spleen, lung, kidney, testis (male), ovary (fema...

Embodiment 2

[0034] The human amniotic epithelial cells used in this example are the P3 generation cells isolated and cultured from human amniotic membrane, and 40 8-week-old IL-10-deficient mice (female mice) were purchased and raised under SPF (Specific Pathogen Free, no specific pathogen) conditions. 20 mice, 20 male mice), were evenly divided into two groups, an experimental group and a control group, with 20 mice in each group (10 female mice, 10 male mice). Before the experiment, blood was collected from the submandibular vein of each mouse, and the levels of inflammatory factors IL-6, IL-1β, TNF-α and IFN-γ in the serum were determined by MSD ultra-sensitive electrochemiluminescence method, and then the experimental group was given therapeutic agents (components : Including 1×10 6 Human amniotic epithelial cells (0.5mL normal saline), the control group was given placebo (ingredient: 0.5mL normal saline), tail vein injection administration. After 8 weeks, blood was collected from ea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of human amniotic epithelial cells in preparation of a medicine for preventing or treating senile asthenia, and belongs to the technical field of biology. The senile asthenia comprises senile asthenia or the early stage of senile asthenia, an effective dose of human amniotic epithelial cells or cell preparations thereof are used independently or in combination with other medicines for preventing or treating senile asthenia, the human amniotic epithelial cells are cells collected without any treatment, partially purified cells or purified cells proliferated through artificial culture, and the effective dose of each time is 1*106-1*1010 cells. The human amniotic epithelial cells used in the application are simple and convenient in separation method, free of ethics problems and tumorigenicity, have multi-directional differentiation and immune regulation capacity, have good safety and effectiveness when used for preventing and treating senile asthenia, and improve the living state of senile asthenia people and the living quality of senile asthenia people.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to the use of human amniotic epithelial cells in the preparation of medicines for preventing or treating senile debilitating diseases. Background technique [0002] It is generally believed that frailty is a common geriatric syndrome, mainly manifested in increased vulnerability of the body, decreased ability to maintain homeostasis, and increased risk of morbidity and mortality. Its core feature is the decline in the reserve function of multiple physiological systems. Frailty is not only manifested as physical dysfunction, but also a psychological disorder, which is related to disability and disease (common) disease, but it is not the same as disability or disease. Patients with senile frailty may not have disability or comorbidity, but only manifest Fatigue, emaciation, depression, etc., its disability rate and mortality rate are significantly higher than those of non-frail...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/50A61K45/06A61P39/00A61P39/06
CPCA61K35/50A61K45/06A61P39/00A61P39/06
Inventor 姬广超王晓明刘倩
Owner 上海安库生医生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap